- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00472758
A Multicenter Study to Evaluate the Safety and Tolerability of Single-Dose for MEDI-545 (CP145)
November 16, 2011 updated by: MedImmune LLC
A Phase 1, Randomized, Double-blind, Placebo-controlled, Dose-escalation, Multicenter Study to Evaluate the Safety and Tolerability of Single-Dose, Intravenously Administered MEDI-545, a Fully Human Anti-Interferon-Alpha Monoclonal Antibody, in Patients With Chronic Plaque Psoriasis
-To evaluate the safety and tolerability of a multiple doses of this drug in adult patients.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
-The primary objective of the study is to evaluate the safety and tolerability of escalating single IV doses of MEDI-545 in adult patients with chronic plaque psoriasis.
Study Type
Interventional
Enrollment (Actual)
40
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Laval-Quebec, Canada, H7S 2C5
- Innovaderm Research, Laval, Inc.
-
Montreal, Canada, H2K 4L5
- Innovaderm Research, Inc.
-
Waterloo- Ontario, Canada, N2J 1C4
- Probity Medical Research
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 70 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Male or female adults, age 18 through 70 years of age at time of screening;
- Written informed consent obtained from the patient prior to receipt of any study medication or beginning study procedures;
- Documented clinical history of chronic plaque psoriasis;
- ≥ 3% body surface area (BSA) involvement in affected skin other than the face and scalp;
- Have at least two target plaques that are suitable for serial photographic assessments, one of which is of a size and location to allow serial biopsies;
- No significant changes in regular psoriasis treatment from at least 28 days from screening through the time of study drug administration;
- Sexually active women, unless surgically sterile or at least 1 year post-menopausal, must use an effective method of avoiding pregnancy (including oral, transdermal, or implanted contraceptives, intrauterine device, female condom with spermicide, diaphragm with spermicide, cervical cap, abstinence, use of a condom with spermicide by the sexual partner or sterile sexual partner) for 21 days prior to study drug administration, and must agree to continue using such precautions through Study Day 126. Cessation of birth control after this point should be discussed with a responsible physician. Sexually active men, unless surgically sterile, must likewise use an effective method of birth control (condom with spermicide) and must agree to continue using such precautions through Study Day 126;
- Willing to forego other forms of experimental treatment and study procedures during the study; and
- Ability to complete the study period, including follow-up period through Study Day 126.
Exclusion Criteria:
- Receipt of MEDI-545 in any previous clinical study;
- History of allergy or reaction to any component of the MEDI-545 formulation;
- Pustular, guttate, or erythrodermic psoriasis as the predominant disease type;
- Current use of potent topical corticosteroids, tacrolimus, or calcipotriol from 28 days prior to screening through study drug administration;
- Current use of phototherapy including tanning beds, Goeckerman or modified Goeckerman regimen, systemic corticosteroids, cyclosporin A, azathioprine, mycophenolate mofetil, methotrexate, or any other systemic treatment for psoriasis within 28 days prior to screening up through study drug administration;
- Current use of biologic agents such as alefacept or tumor necrosis factor-α inhibitors within 90 days prior to screening up through study drug administration;
- Any disease or illness, other than chronic plaque psoriasis, that may require the use of systemic corticosteroids during the study period;
- Acute illnesses or evidence of significant active infection, such as fever ≥ 38.0°C (≥ 100.5°F) from screening through study drug administration;
- Receipt of any investigational drug therapy or attenuated live vaccine therapy (other than vaccination against influenza) within 30 days or 5 half-life periods (whichever is longer) prior to study drug administration through the end of study;
- Pregnancy (sexually active women, unless surgically sterile or at least 1 year post-menopausal, must have a negative serum pregnancy test at screening and a negative urine pregnancy test prior to study drug administration on Study Day 0);
- Breastfeeding or lactating women;
- Evidence of infection with hepatitis B or C virus, or human immunodeficiency virus (HIV)-1 or -2, or active infection with hepatitis A, as determined by results of testing at screening;
- A history of severe infection with cytomegalovirus or viruses of the herpes family including Epstein-Barr virus requiring hospitalization, disseminated herpes, herpes encephalitis, or ophthalmic herpes;
- Herpes zoster within 3 months prior to screening;
- Current suppressive antiviral therapy for herpes or other viral infections;
- A history of cancer except basal cell carcinoma or in situ carcinoma of the cervix treated with apparent success with curative therapy ≥ 1 year prior to randomization;
- Elective surgery planned during the study period through end of study;
- Clinically significant abnormality, as determined by the investigator, on 12-lead electrocardiogram (ECG) or chest radiograph at screening;
- A history of coagulation disorders;
- History of primary immunodeficiency;
- History of stroke, or any cerebrovascular disease requiring current medication/treatment;
- In the opinion of the investigator, clinically significant active cardiac disease, including: unstable angina; myocardial infarction within 6 months; congestive heart failure; or arrhythmia requiring active therapy;
- Ongoing, clinically significant (in the opinion of the investigator) chronic infectious disease;
- History of active tuberculosis or positive tuberculosis (TB) test (defined as a reaction ≥ 10 mm in diameter) without a completed course of appropriate medical treatment;
- At the time of screening, any of the following: clinically significant abnormalities of hemoglobin, total white blood cell count, or platelet count; aspartate transaminase (AST) or alanine transaminase (ALT) > 1.5 times the upper limits of normal (ULN), serum creatinine, and prothrombin time (PT) or partial thromboplastin time (PTT) > ULN;
- Any other abnormal laboratory values in the screening panel that, in the opinion of the investigator, are clinically significant. Abnormal results on screening laboratory tests may be repeated once at the discretion of the site investigator(s) or qualified designee, prior to Study Day 0, to determine eligibility; or
- Evidence of any systemic disease or skin disease (other than chronic plaque psoriasis), any finding upon physical examination or history of any disease that, in the opinion of the investigator, designated health care provider, or medical monitor, may compromise the safety of the patient in the study or confound the analysis of the study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: 1
MEDI 545
|
IV dosed at 1.0 mg/kg, 3.0,g/kg, 10.0mg/kg and 30.0mg/kg
|
Placebo Comparator: 2
Placebo IV
|
IV Placebo dosed at 1.0 mg/kg, 3.0,g/kg, 10.0mg/kg and 30.0mg/kg
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Safety and tolerability of MEDI-545 will be assessed through the collection of AEs and SAEs from study drug administration through Study Day 126.
Time Frame: Through day 26
|
Through day 26
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Secondary endpoints are the PK and IM of single-dose IV MEDI-545.
Time Frame: determination not stated
|
determination not stated
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Barbara White, M.D., MedImmune LLC
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
February 1, 2007
Primary Completion (Actual)
February 1, 2008
Study Completion (Actual)
March 1, 2008
Study Registration Dates
First Submitted
May 11, 2007
First Submitted That Met QC Criteria
May 11, 2007
First Posted (Estimate)
May 14, 2007
Study Record Updates
Last Update Posted (Estimate)
November 17, 2011
Last Update Submitted That Met QC Criteria
November 16, 2011
Last Verified
November 1, 2011
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- MI-CP145
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Plaque Psoriasis
-
UCB Biopharma SRLRecruitingModerate Chronic Plaque Psoriasis | Severe Chronic Plaque Psoriasis | Mixed Guttate/Plaque PsoriasisUnited States, Canada, Puerto Rico
-
UCB Biopharma SRLCompletedModerate to Severe Chronic Plaque Psoriasis | Chronic Plaque PsoriasisUnited States, Australia, Belgium, Canada, Germany, Hungary, Italy, Japan, Korea, Republic of, Poland, Russian Federation, Taiwan, United Kingdom
-
UCB Biopharma SRLCompletedModerate to Severe Chronic Plaque Psoriasis | Chronic Plaque PsoriasisUnited States, Australia, Belgium, Canada, France, Germany, Netherlands, Poland, Spain, Turkey, United Kingdom
-
Biocon Biologics Inc.MEDA Pharma GmbH & Co. KG; Mylan Inc.; IQVIA Pvt. LtdCompletedHulio Interchangeability to Humira®, Comparing Pharmacokinetics, Efficacy, Safety and ImmunogenicityModerate Chronic Plaque Psoriasis | Severe Chronic Plaque PsoriasisBulgaria, Czechia, Estonia, Poland
-
UCB Biopharma SRLActive, not recruitingModerate to Severe Chronic Plaque Psoriasis | Chronic Plaque PsoriasisChina
-
UCB Biopharma SRLCompletedModerate to Severe Chronic Plaque Psoriasis | Chronic Plaque PsoriasisUnited States, Canada
-
UCB Biopharma SRLCompletedModerate to Severe Plaque Psoriasis | Chronic Plaque PsoriasisUnited States, Australia, Canada, Germany, Hungary, Korea, Republic of, Poland, Russian Federation, Taiwan
-
AbbVieCompletedChronic Plaque PsoriasisUnited States, Austria, Canada, Czechia, Denmark, France, Germany, Greece, Ireland, Netherlands, Puerto Rico, Spain, Sweden, United Kingdom
-
AbbVieActive, not recruitingChronic Plaque PsoriasisArgentina, Australia, Austria, Canada, Colombia, Czechia, France, Germany, Hungary, Ireland, Italy, Japan, Mexico, Netherlands, Poland, Romania, Saudi Arabia, Spain, Switzerland, United Arab Emirates, United Kingdom
-
UCB Biopharma SRLCompletedPsoriatic Arthritis | Moderate to Severe Chronic Plaque Psoriasis | Chronic Plaque PsoriasisUnited States, Australia, Canada, Germany, Hungary, Korea, Republic of, Poland, Russian Federation, United Kingdom
Clinical Trials on MEDI 545
-
AstraZenecaMedImmune LLCCompletedSystemic Lupus ErythematosusJapan
-
MedImmune LLCCompletedLupusUnited States, Canada
-
University of PaviaIRCCS Policlinico S. MatteoUnknown
-
MedImmune LLCCompletedA Study to Evaluate Safety and Tolerability of Subcutaneous Doses of MEDI-545 in Subjects With LupusLupus Erythematosus, Systemic | LupusUnited States
-
MedImmune LLCCompletedDERMATOMYOSITIS OR POLYMYOSITISUnited States
-
MedImmune LLCCompletedLupusBrazil, United States, Chile, Argentina
-
MedImmune LLCCompletedSystemic Lupus ErythematosusUnited States, Brazil, Bulgaria, France, Italy, Mexico, Peru, Poland, South Africa, Spain, United Kingdom, Germany, Hungary, Romania, Argentina, Canada, Chile, Netherlands, India, Jamaica, Philippines, Thailand
-
MedImmune LLCAstraZenecaTerminatedLupus Erythematosus, SystemicUnited States, Mexico, Peru, South Africa, Canada
-
European Malaria Vaccine InitiativeRadboud University Medical Center; GlaxoSmithKline; Biomedical Primate Research... and other collaboratorsCompletedPlasmodium Falciparum MalariaNetherlands
-
MedImmune LLCCompletedCancer | Graft-Versus-Host DiseaseUnited States